NCT05413655招募中2 期
A Phase 2, Randomized, Double Blind, Placebo-Controlled Study of Oral EX039 As Add-on to Acetylcholine Esterase Inhibitors in Subjects with Mild Alzheimer's Disease
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- Excelsior
- 入组人数
- 120
- 试验地点
- 1
- 主要终点
- Change in Alzheimer's Disease Assessment Scale-cognitive
研究概览
简要总结
This is a phase 2, randomized, double-blind, placebo-controlled study of oral EX039 as add-on to Acetylcholine Esterase Inhibitors in subjects with mild Alzheimer's disease.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 50 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Aged 50-80 years.
- •Clinical diagnosis of probable mild Alzheimer disease dementia based on National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA criteria, 2011)
- •Last time (which must be within 3 months ) of Mini Mental State Exam (MMSE) between 10-
- •Last time (which must be within 3 months) of Clinical Dementia Rating (CDR) score of
- •Physically healthy and all laboratory assessments (including hematology, chemistry, urinalysis and electrocardiograph) are within normal range or meet the following criteria:
- •AST, ALT level ≦ upper limit of normal
- •Creatine Kinase (CK) concentration more than 3 times upper limit of normal
- •Serum creatinine level ≦ upper limit of normal
- •HbA1c more than 8.0
- •Complaints of subjective memory impairment and cognitive disturbances by patients themselves or caregivers, including memory loss and at least one of the following cognitive disturbances: language, perceptual skills, attention, constructive abilities, orientation, problem solving, functional abilities.
- •Cognitive deficits caused impairment in social or occupational function.
- •Disease progression with gradual and continued decline from a previous level of functioning.
- •Female subjects must be of non-childbearing potential (greater than 1 year without menstrual period in the absence of hormone replacement therapy) or surgically sterile. If pre-menopausal or menopausal for 1 year or less, must have a negative pregnancy test and must not be lactating at screening visit. Female subjects of childbearing potential and who are sexually active are required to practice adequate methods of birth control. Male subjects who are sexually active will also be required to use an adequate form of birth control.
- •Has sufficient education equivalent to elementary education to communicate effectively and were capable of completing the assessments of the study.
排除标准
- •Having other causes of dementia.
- •Having substantial concomitant cerebrovascular disease (defined by a history of a stroke
- •/ intracranial hemorrhage temporally related to the onset of worsening of cognitive impairment) per investigator judgement.
- •Medical history of cancer (except for basal cell carcinoma) and/or treatment for cancer within the last 5 years.
- •Medical history or diagnosis of any of the following symptomatic and unstable / uncontrolled conditions per investigator's judgement:
- •Uncontrolled cardiovascular illnesses such as chronic congestive heart failure (with or without edema), tachycardia, arrhythmias, uncontrolled hypertension.
- •Significant ischemic heart disease, myocardial infarction within the last two years and/or with residual angina, orthopnea, conduction defects (ECG), or any other clinical significant heart disease classified as New York Heart Association (NYHA) III or IV.
- •Significant gastrointestinal disorders (for example gastrointestinal bleeding within the last two years, malabsorption syndromes, post-gastrectomy, or active peptic ulcer disease).
- •Uncontrolled endocrine disease such as uncontrolled diabetes mellitus or hyperthyroidism.
- •Unstable/Uncontrolled major depression.
- •Has neurological disease (other than dementia of Alzheimer's type, such as: Lewy body dementia - primary diagnosis, Huntington's disease, Parkinson's Disease, encephalitis, epilepsy, vascular or multiinfarct dementia, stroke, congenital mental deficiency, multiple sclerosis).
- •Significant pulmonary disease predisposing to hypoxia.
- •Has major physical illnesses (e.g. brain tumor, craniocerebral trauma, thyroid disease)
- •Any other psychiatric disorders such as schizophrenia, or mental retardation.
- •Any suicidal actions in the past 2 years (per investigator judgement i.e. actual attempt, interrupted attempt, aborted attempt, or preparatory acts or behavior).
- •Hachinski Ischemic Score > 4
- •Significant history of drug dependence or abuse (including alcohol, as defined in Diagnostic and Statistical Manual of Mental Disorders [DSM-V] or in the opinion of the investigator)
- •Clinically significant uncompensated hearing loss in the judgment of the investigator. Use of hearing aids is allowed.
- •Has other condition(s) that in the opinions of investigators to be ineligible to participate in this study, e.g. Subject who cannot swallow the capsule whole.
研究组 & 干预措施
1000 mg
Experimental
The recruited patient randomly assigned to this arm will take 1000 mg EX039 per day
干预措施: EX039 (Drug)
750 mg
Experimental
The recruited patient randomly assigned to this arm will take 750 mg EX039 per day
干预措施: EX039 (Drug)
placebo
Placebo Comparator
The recruited patient randomly assigned to this arm will take placebo per day
干预措施: Placebo (Drug)
结局指标
主要结局
Change in Alzheimer's Disease Assessment Scale-cognitive
时间窗: Week 28
Mean change from baseline in Alzheimer's Disease Assessment Scale-cognitive subscale measured at the end of week 28. Total scores range from 0-70, with higher scores (≥ 18) indicating greater cognitive impairment.
Change in Clinical Dementia Rating-Sum of Boxes
时间窗: Week 28
Mean change from baseline in Clinical Dementia Rating-Sum of Boxes (CDR-SB). measured at the end of week 28. Total scores range from 0 to 18, with higher scores indicating more worsening.
次要结局
- Change in Clinician's Interview-Based Impression of Change Plus Caregiver Input(Week 4, 12, 20, 28)
- Incidence of Treatment-Emergent Adverse Events(Week 30)
- Responder rate assessment(Week 28)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Effect of Oral (Z)-Endoxifen in Premenopausal Women With Measurable Breast DensityBreast DensityNCT05068388Atossa Therapeutics, Inc.240
已完成
2 期
A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer's DiseaseAlzheimer DiseaseNCT04592874Alector Inc.356
撤回
2 期
Study of CAD-1883 for Spinocerebellar AtaxiaSpinocerebellar AtaxiasSpinocerebellar Ataxia Type 1Spinocerebellar Ataxia Type 2Spinocerebellar Ataxia Type 6Spinocerebellar Ataxia Type 7Spinocerebellar Ataxia Type 8Spinocerebellar Ataxia Type 10Spinocerebellar Ataxia Type 17ARCA1 - Autosomal Recessive Cerebellar Ataxia Type 1Spinocerebellar Ataxia Type 3NCT04301284Cadent Therapeutics
已完成
2 期
A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications.RSV InfectionNCT05568706Enanta Pharmaceuticals, Inc187
已完成
2 期
A Study of CST-2032 and CST-107 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's or Alzheimer's DiseaseMild Cognitive ImpairmentDementiaNCT05104463CuraSen Therapeutics, Inc.64